The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes and characterization of HER2 alterations in non-small cell lung cancer (NSCLC).
 
Nikita Dahake
No Relationships to Disclose
 
Yasmine Baca
Employment - Caris Life Sciences
 
Ilya Serebriiskii
No Relationships to Disclose
 
Joanne Xiu
Employment - Caris Life Sciences
 
Erica Golemis
No Relationships to Disclose
 
George Sledge
Employment - Caris Life Sciences
Leadership - Caris Life Sciences; Syndax
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
David Spetzler
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Caris Life Sciences
Research Funding - Caris Life Sciences
Patents, Royalties, Other Intellectual Property - Caris Life Sciences holds and has pending patents with intellectual property interests relating to health and medicine.
Travel, Accommodations, Expenses - Caris Life Sciences
 
Stephen Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech; Gilead Sciences; GlaxoSmithKline; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merus; Mirati Therapeutics; MSD Oncology; Natera; Novartis; OSE Immunotherapeutics; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Takeda; Yuhan
Research Funding - Abbvie (Inst); Alkermes (Inst); AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Cogent Biosciences (Inst); Duality Biologics (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Systimmune (Inst)
(OPTIONAL) Uncompensated Relationships - Roche/Genentech
 
Balazs Halmos
Consulting or Advisory Role - Apollomics; Arcus Biosciences; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Genentech/Roche; Janssen Oncology; Lilly; Merck; merus; Novartis; Nuvalent, Inc.; Pfizer; Takeda; Turning Point Therapeutics; Veracyte
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen; AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Elevation Oncology (Inst); Forward (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Takeda (Inst); Tesaro/GSK (Inst)
 
Paul Stockhammer
No Relationships to Disclose
 
Michael Grant
Honoraria - Daiichi Sankyo/Astra Zeneca
Consulting or Advisory Role - Regeneron
Research Funding - Adela (Inst)
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Pfizer; Regeneron
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bayer; Beigene; BerGenBio; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; Genmab; Grid Therapeutics; Guardant Health; IO Biotech; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; natera; Novartis; oncocyte; Pfizer; PharmaMar; Puma Biotechnology; RAPT Therapeutics; Regeneron; Rgenix; Sonnet; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Mirati Therapeutics; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Julia Judd
No Relationships to Disclose